

Mycosis Fungoides

What is Mycosis Fungoides (MF)?


- Mycosis Fungoides (MF) is a T cell lymphoma which occurs in the skin; it is the most common type of cutaneous T cell lymphoma (CTCL).
- This cancer is highly symptomatic and disfiguring and is life threatening in advanced stages. There are no reported spontaneous remissions for MF patients.
- Symptoms include red skin rashes progressing through 4 phases leading to patches, a plaque, and eventually tumors.*
- The primary hypotheses for the pathophysiology of MF include either a foreign antigen that consistently activates the immune system or a viral infection similar to a virus associated with T-cell leukemia.
- Men are more likely to develop MF than women.
- There are an estimated 16,000 to 20,000 cases of MF in the US.*

Patient Impact

- CTCLs including mycosis fungoides are lifelong disorders with no cure.
- MF causes patients to have suppressed immune systems leading to systemic infections and secondary malignancies.
- Large rashes can cause patients emotional and mental distress alongside the physical symptoms.
- Mortality rates are approximately 3x compared to the general public and one in five MF patients will progress to a highly malignant lymphoma with widespread dissemination to other organs of the body.*

Treatment Options

- Treatment begins with topical steroids and other symptomatic treatments for the skin rashes.
- Systemic treatments include interferon, chemotherapeutic agents including pentostatin, gemcitabine, doxorubicin, and oral retinoids.
- Other combination chemotherapies are used sparingly due to only modest response and potential for infectious complications.



Survival rates of MF patients at different stages of the disease after diagnosis.

Source: H. Miles Prince, Sean Whittaker and Richard T. Hoppe
Blood 2009 114:4337-4353; doi:10.1182/blood-2009-07-202895

Mycosis fungoides patients have few treatments that give long term benefits without toxicities or immunosuppression.

About KPI Therapeutics™:

KPI Therapeutics is a clinical stage biotechnology company, which develops first in class therapies for unmet medical needs in autoimmunity using its novel Kv1.3 channel blocker based platform. Its lead drug, dalazatide is being clinically advanced for Inclusion Body Myositis, (IBM) an orphan disease, and for lupus. Our autoimmune platform molecules are also being developed for new therapies to address atopic dermatitis and uveitis.

Our autoimmune program is developing a systemic biologic Kv1.3 inhibitor targeting the immune cells that cause Mycosis Fungoides.

www.kpitherapeutics.com | 206-788-4600

* <https://www.cancer.gov/types/lymphoma/patient/mycosis-fungoides-treatment-pdq>